City Therapeutics: President & CEO Andrew C. Orth received 77,979 shares

What happened Andrew C. Orth, president & CEO and director, acquired 77,979 shares on Oct 19, 2026, at $0.00 per share for a total of $0 (derivative acquisition under transaction code A). The filing notes the underlying stock option was originally granted on Dec 11, 2024 and the shares vested in full upon closing of the issuer's initial public offering on Oct 19, 2026.

Key details

• Transaction date and price: Oct 19, 2026; $0.00 per share; total $0.
• Transaction type: Award/grant/other acquisition (code A), derivative.
• Shares owned after the transaction: Not reported in the filing.
• Footnote F1: Option granted Dec 11, 2024; shares vested in full upon closing of the IPO on Oct 19, 2026.
• Filing date and timeliness: Filed on Oct 19, 2026; no late filing indicated.

Why it may matter

• The filing shows vested options converted into shares; no sale or cashless exercise is reported in this Form 4.
• A filing does not show why the insider traded or why the company acted.